If you have metastatic breast cancer, you may need help from loved ones and your medical team along the way. Here’s how to ...

Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.

A Peter Mac-led international clinical trial has shown adding an immunotherapy drug to the chemotherapy that patients receive ...

A far shorter, simpler, and less toxic treatment protocol for patients with triple-negative breast cancer produced outcomes ...

Maintaining treatment with CDK4/6 inhibitors significantly suppresses the growth of breast cancer cells, even after drug resistance has developed, according to new research.

The response of ER+/HER2– breast cancer to treatment varies widely, which not only affects clinical outcomes but can pose a challenge to the effective medical management of the condition.

One of the most important launches for Novartis in recent years is off with a bang. | One of the most important launches for ...

The researchers found that imlunestrant prolonged progression-free survival (PFS) when compared to standard care in patients with ESR1 mutations, but there was no PFS benefit observed in the overall ...

Researchers say lerociclib plus fulvestrant could become a new treatment option for HR+/HER2- advanced breast cancer, but lerociclib is not approved in the US.

Jan. 28, 2025 — A new study shows that asymptomatic brain metastasis is more common in stage 4 breast cancer patients than previously believed. The study suggests that doctors may need to ...

Several new treatment options for patients with breast cancer have emerged over the last few years, including more oral ...

Researchers Discover a Genetic Disposition Increasing the Risk of Breast Cancer Metastasis Dec. 9, 2024 — Metastasis is responsible for 90 percent of cancer deaths. Researchers have found that ...